WO2003045387A1 - Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative - Google Patents
Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative Download PDFInfo
- Publication number
- WO2003045387A1 WO2003045387A1 PCT/HU2002/000132 HU0200132W WO03045387A1 WO 2003045387 A1 WO2003045387 A1 WO 2003045387A1 HU 0200132 W HU0200132 W HU 0200132W WO 03045387 A1 WO03045387 A1 WO 03045387A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloride
- propoxy
- benzimidoyl
- metformin
- acid addition
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960003105 metformin Drugs 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 239000013543 active substance Substances 0.000 title abstract description 19
- 150000002443 hydroxylamines Chemical class 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 239000002253 acid Chemical group 0.000 claims abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract description 5
- 125000005059 halophenyl group Chemical group 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 125000006501 nitrophenyl group Chemical group 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 4
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 3
- 239000001301 oxygen Substances 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- WFPFEBXJYWAZGV-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)propoxy]pyridine-3-carboximidoyl chloride Chemical compound C1CN(C)CCN1CCCON=C(Cl)C1=CC=CN=C1 WFPFEBXJYWAZGV-UHFFFAOYSA-N 0.000 claims description 4
- LJBVWYLJNYJTMN-UHFFFAOYSA-N 3-chloro-n-(3-piperidin-1-ylpropoxy)benzenecarboximidoyl chloride Chemical compound C=1C=CC(Cl)=CC=1C(Cl)=NOCCCN1CCCCC1 LJBVWYLJNYJTMN-UHFFFAOYSA-N 0.000 claims description 3
- KSHHFWADNHWFCS-UHFFFAOYSA-N 3-nitro-n-(3-piperidin-1-ylpropoxy)benzenecarboximidoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=NOCCCN2CCCCC2)=C1 KSHHFWADNHWFCS-UHFFFAOYSA-N 0.000 claims description 3
- YPYPGVJUZIEFDQ-UHFFFAOYSA-N n-(2-hydroxy-3-piperidin-1-ylpropoxy)benzenecarboximidoyl chloride Chemical compound C1CCCCN1CC(O)CON=C(Cl)C1=CC=CC=C1 YPYPGVJUZIEFDQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 6
- 102000004877 Insulin Human genes 0.000 abstract description 3
- 108090001061 Insulin Proteins 0.000 abstract description 3
- 229940125396 insulin Drugs 0.000 abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 20
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 229960001681 croscarmellose sodium Drugs 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000010030 glucose lowering effect Effects 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 3
- DAXOEPZCJSADTF-UHFFFAOYSA-N Cl.C1CCCCN1CC(O)CON=C(Cl)C1=CC=CS1 Chemical compound Cl.C1CCCCN1CC(O)CON=C(Cl)C1=CC=CS1 DAXOEPZCJSADTF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- ZBLMDVYHGMWOQD-UHFFFAOYSA-N 2-chloro-N-(2-morpholin-4-ylethoxy)benzenecarboximidoyl chloride hydrochloride Chemical compound Cl.ClC(=NOCCN1CCOCC1)c1ccccc1Cl ZBLMDVYHGMWOQD-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- IAJRBASJKPAYBJ-UHFFFAOYSA-N 3-nitro-n-(3-piperidin-1-ylpropoxy)benzenecarboximidoyl chloride;hydrochloride Chemical compound Cl.[O-][N+](=O)C1=CC=CC(C(Cl)=NOCCCN2CCCCC2)=C1 IAJRBASJKPAYBJ-UHFFFAOYSA-N 0.000 description 2
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- CORXGUUQHWVVIA-UHFFFAOYSA-N Cl.ClC(=NOCCCN1CCCCC1)c1cccc(Cl)c1 Chemical compound Cl.ClC(=NOCCCN1CCCCC1)c1cccc(Cl)c1 CORXGUUQHWVVIA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229940093462 metformin hydrochloride 250 mg Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- HPNBPCVAJIMXAR-UHFFFAOYSA-N n-(2-hydroxy-3-piperidin-1-ylpropoxy)benzenecarboximidoyl chloride;hydrochloride Chemical compound Cl.C1CCCCN1CC(O)CON=C(Cl)C1=CC=CC=C1 HPNBPCVAJIMXAR-UHFFFAOYSA-N 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
- VEIIWKVRVGKMBB-UHFFFAOYSA-N 1-(3-piperidin-1-ylpropoxy)-2H-pyridine Chemical compound N1(CCCCC1)CCCON1CC=CC=C1 VEIIWKVRVGKMBB-UHFFFAOYSA-N 0.000 description 1
- XKXGWXKZHPYRMQ-UHFFFAOYSA-N 1-methyl-4-[3-(2H-pyridin-1-yloxy)propyl]piperazine Chemical compound CN1CCN(CC1)CCCON1CC=CC=C1 XKXGWXKZHPYRMQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MDNFGNHIELARIM-UHFFFAOYSA-N Cl.Cl.Cl.C1CN(C)CCN1CCCON=C(Cl)C1=CC=CN=C1 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1CCCON=C(Cl)C1=CC=CN=C1 MDNFGNHIELARIM-UHFFFAOYSA-N 0.000 description 1
- MUQLIPKRDBMINA-UHFFFAOYSA-N Cl.ClC(=NOCCCN1CCCCC1)c1cccnc1 Chemical compound Cl.ClC(=NOCCCN1CCCCC1)c1cccnc1 MUQLIPKRDBMINA-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- UETQVDZZPKAQIC-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl.Cl UETQVDZZPKAQIC-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940103776 metformin hydrochloride 500 mg Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Definitions
- composition with combined active agents containing metformin and a hydroxylamine derivative containing metformin and a hydroxylamine derivative
- the invention relates to a pharmaceutical composition containing a combination of metformin and a hydroxylamine derivative as active agent.
- the composition of the invention can be used in the therapy of the diabetes mellitus, especially in the therapy of type II (non-insulin dependent, NIDDM) diabetes mellitus.
- Metformin i.e. 1 ,1-dimethyl-biguanidin (N,N-dimethylimido-dicarbonimidic diamide) is long since known and widely used biguanidin type antihyperglycemic agent. Contrary to other antihyperglycemic agents it does not influence the insulin secretion, however, it increases the insulin sensitivity of the tissues, inhibits the hepatic glucose production and reduces the glucose absorption. Metformin is used alone or in combination with other antihyperglycemic agents.
- compositions containing metformin alone are known from WO 97/02843, a combination of metformin and glibenclamide, a sulfonylurea type antihyperglycemic agent is known from WO 97/17975 and WO 00/03742, combinations of metformin and thiazolidine-dione derivatives are known from WO 98/57634.
- the sulfonylurea derivatives stimulate the insulin secretion and thus complete the effect of metformin
- the thiazolidine-dione derivatives which are insulin sensitizers strengthen the effect of metformin.
- Metformin and nateglinide a phenylalanine derivative (N-[[trans-4-(1- methylethyl)-cyclohexyl]-carbonyl]-D-phenylalanine) are applied simultaneously in order to hinder the postprandial increase of blood glucose level by nateglinide and thereby reduce the mealtime glucose excursion (Diabetes Care Vol. 23, No 3, March 2000 and Diabetes Care Vol 23, No 11 , November 2000).
- compositions of combined active agents mentioned above are insufficient to reduce the blood glucose at a substantial extent, which results in need of regular administration of insulin after a period of transition as the illness progresses.
- An other disadvantage of combined compositions containing metformin and a sulfonylurea type active agent is that they are not safe as to the exclusion of occurence of hypoglycemia.
- Pharmaceutical compositions containing combinations of metformin with a fibrate, especially fenofibrate or bezafibrate are known from WO 99/40904. Due to the combination of the active ingredients the cholesterol level and the trigliceride level can also be reduced by the treatment besides the reduction of blood glucose, the reduction of the blood glucose, however, does not attain the desired extent.
- metformin should be administered in controlled quantities because of its risk (lactic acidosis) and its unfavourable side effects, mainly some gastrointestinal problems. Therefore, lowering the relative amount of metformin is desirable in pharmaceutical compositions containing metformin in combinations.
- Such an endavour appears from WO 97/17975 mentioned above.
- the invention provides an orally applicable pharmaceutical composition for the treatment of diabetes mellitus which comprises as active principle a combination of metformin (N,N-dimethylimido-dicarbonimidic diamide) or an acid addition salt thereof and a compound of general formula (I) wherein Ar is pyridyl, thienyl, phenyl, halophenyl or nitrophenyl group, X is halo, n has the value of zero or 1 ,
- the compounds of general formula (I) are known chemical substances.
- Compounds corresponding to formula (I) wherein Ar is pyridyl, phenyl or halophenyl group and Y is hydroxy are known from WO 90/04584.
- the process for the preparation of these compounds is also described in the cited paper. These compounds have selective beta-blocking effect and are usable in the therapy of diabetic angiopathy.
- metformin is preferably present in the composition as an acid addition salt formed with a mineral or organic acid such as hydrochloric, hydrobromic, acetic, lactic, oxalic, maleic, malonic, succinic, fumaric, citric, methanesulfonic and p-toluenesulfonic acid, where the hydrochloride and the fumarate are preferred.
- a mineral or organic acid such as hydrochloric, hydrobromic, acetic, lactic, oxalic, maleic, malonic, succinic, fumaric, citric, methanesulfonic and p-toluenesulfonic acid, where the hydrochloride and the fumarate are preferred.
- the compounds of general formula (I) are preferably present in the composition of the invention in the form of an acid addition salt formed with a mineral or organic acid, such as hydrochloric, hydrobromic, maleic, fumaric, p-toluenesulfonic, methanesulfonic, citric and tartaric acid, preferably in the form of hydrochloride, citrate or maleate.
- a mineral or organic acid such as hydrochloric, hydrobromic, maleic, fumaric, p-toluenesulfonic, methanesulfonic, citric and tartaric acid
- the weight ratio of metformin to the compound of general formula (I) varies between 5:1 and 100:1 , more preferably between 10:1 and 25:1 in the combination of active ingredients.
- the pharmaceutical composition of the invention is prepared by mixing the two active principles and vehicles and optionally auxiliary materials usually applied in the pharmaceutical industry in a conventional way.
- the compositions of the invention are formulated for oral application into tablets, coated tablets, dragees, granulates, capsules, solutions or syrups.
- the solid forms of the composition can contain fillers, such as microcrystalline cellulose, starch and lactose, lubricants, such as stearic acid and magnesium stearate, coating materials, such as sugar, film forming materials, such as hydroxymethyl cellulose or hydroxypropyl methyl cellulose as well as conventional flavors and colors.
- the capsule formulations can be prepared with use of hard or soft gelatin capsules.
- the pharmaceutical compositions of the invention are prepared in unit dosage forms for administering two or three times per day.
- the daily dose of metformin is preferably 1000-2000 mg, that of the compound of general formula (I) is preferably 10-400 mg, the exact dose depending on the weight and age and the condition of the patient. These amounts are calculated for the base form of the active principles.
- One unit dosage form contains the corresponding amounts of active agents, the metformin preferably as an acid addition salt thereof and the compound of general formula (I) preferably also in the form of an acid addition salt thereof.
- the invention relates to a method of treatment of diabetes mellitus comprising administering to the patient a combination of metformin (N,N-dimethylimido-dicarbonimidic diamide) or an acid addition salt thereof and a hydroxylamine derivative of general formula (1) wherein Ar, X, Y, Z and n have the above meanings or an acid addition salt thereof.
- metformin N,N-dimethylimido-dicarbonimidic diamide
- Ar, X, Y, Z and n have the above meanings or an acid addition salt thereof.
- mice Groups of male Wistar rats of 300-350 g body weight, at least 6 animals in each group were used in the experiments. The animals fasting at least 14 hours were treated intravenously with 40 mg/kg streptozotocin (STZ) freshly dissolved in physiological saline in order to induce diabetes. The concentration of the stock solution was 40 mg/ml and the applied amount was 0,1 ml/100g.
- STZ streptozotocin
- mice were placed in rat stocks after a period of 24 hours following the STZ treatment. 1-1 ,5 mm of tips of tails were cut by scissors and at least 200 ⁇ l blood samples were taken into Eppendorf tubes. The blood samples were centrifuged at 2500 rpm while cooling (4 °C). In the obtained sera the blood glucose levels were measured by Vitros 250 automatic analyzer. Animals having a non-fasted serum glucose level over 15 mmol/liter were considered diabetic. The test compounds were applied orally in 10 mg/kg doses (calculated for the base). Metformin was applied in 250 mg/kg p. o. doses. One group of animals was treated with a compound of general formula (I) alone, other groups were treated with metformin, and a combination of metformin and a compound of general formula (I), respectively, for two weeks after the time of demonstrating that diabetes had been developed.
- the invention also relates to the use of 3-nitro-N-[3-(piperidin-1- yl)-propoxy]-benzimidoyl-chloride, N-[2-hydroxy-3-(piperidin-1 -yl)-propoxy]- benzimidoyl-chloride, N-[3-(4-methyl-piperazin-1-yl)-propoxy]-pyridine-3- carboximidoyl-chloride, 3-chloro-N-[3-(piperidin-1-yl)-propoxy]-benzimidoyl- chloride and 2-chloro-N-[2-morpholin-4-yl)-ethoxy]-benzimidoyl-chloride and acid addition salts of these compounds in the preparation of orally applicable pharmaceutical compositions for the treatment of diabetes mellitus.
- the medicines of this kind can be prepared preferably in unit dosage form with an amount of active agent sufficient for 2-3 administrations per day.
- the daily dose of the active agent (calculated for the base form) is 10-400 mg.
- the pharmaceutical compositions can be prepared preferably in form of tablets, coated tablets, dragees, granulates, capsules, solutions or syrups with usually applied excipients in the conventional way, similarly as the above mentioned medicines containing a combination of two active agents.
- the invention also relates to a method of treatment of diabetes mellitus comprising the administration of one of 3-nitro-N-[3-(piperidin-1-yl)-propoxy]- benzimidoyl-chloride, N-[2-hydroxy-3-(piperidin-1 -yl)-propoxy]-benzimidoyl- chloride, N-[3-(4-methyl-piperazin-1-yl)-propoxy]-pyridine-3-carboximidoyl- chloride, 3-chloro-N-[3-(piperidin-1-yl)-propoxy]-benzimidoyl-chloride and 2- chloro-N-[2-morpholin-4-yl)-ethoxy]-benzimidoyl-chloride and acid addition salts thereof to the patient.
- Metformin hydrochloride, N-[2-hydroxy-3-(piperidin-1 -yl)-propoxy]-thiophene- 2-carboximidoyl-chloride hydrochloride, around a half of microcrystalline cellulose and croscarmellose sodium are blended in a planetary mixer.
- An aqueous solution of polyvinyl pyrrolidone is added and the mixture is wet granulated.
- the granules are dried at 60 °C, sieved and introduced into a cone blender.
- Magnesium stearate and the remaining portion of microcrystalline cellulose are added and the mixture is homogenized. The mix is filled in a tablet press and formed into tablets.
- Tablet Tablets are prepared in the way as described in Example 1 with the following composition: metformin hydrochloride 250 mg
- Capsulated medicine is prepared with the following composition: metformin hydrochloride 250 mg 3-chloro-N-[3-(1-piperidinyl)-propoxy]-benzimidoyl chloride hydrochloride 50 mg polyvinyl pyrrolidone 20 mg starch 25 mg talc 3 mg lactose 80 mg
- the active principles, the fillers and the auxiliaries are blended in a planetary mixer and the mixture is wet granulated with water.
- the granules are dried at 60 °C and sieved.
- the granules are filled into hard gelatine capsules.
- Coated tablets are prepared with the following composition: metformin hydrochloride 800 mg 2-chloro-N-[2-(morpholin-4-yl)-ethoxy]-benzimidoyl chloride hydrochloride 10 mg polyvinyl pyrrolidone 20 mg croscarmellose sodium 15 mg microcrystalline cellulose 55 mg magnesium stearate 10 mg hydroxypropyl methylcellulose (film coating) 12 mg
- the tablets are prepared as described in Example 1.
- Granules are prepared by wet granulating from the active principles and the required auxiliary materials. The granules are mixed with the tabletting materials and pressed into tablets. The tablets are coated with hydroxypropyl methylcellulose film.
- Coated tablets are prepared as described in Example 4 with the following composition: metformin hydrochloride 600 mg
- a tabletted composition containing a single active agent is prepared in the way as described in Example 1 with the following ingredients: 3-nitro-N-[3-(piperidin-1-yl)-propoxy]-benzimidoyl-chloride hydrochloride 50 mg polyvinyl pyrrolidone 18 mg croscarmellose sodium 15 mg magnesium stearate 7 mg microcrystalline cellulose 60 mg
- Example 7 Capsule A capsulated medicine containing a single active agent is prepared as described in Example 3 with the following composition: N-[3-(4-methyl-piperazin-1-yl)-propoxy]-pyridine-
- a pharmaceutical composition containing a single active agent is prepared in form of coated tablets in the way as described in Example 4 with the following ingredients: 3-chloro-N-[3-(piperidin-1-yl)-propoxy]-benzimidoyl chloride hydrochloride 80 mg polyvinyl pyrrolidone 18 mg croscarmellose sodium 15 mg microcrystalline cellulose 60 mg magnesium stearate 7 mg hydroxypropyl methylcellulose (film coating) 8 mg
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002347402A AU2002347402A1 (en) | 2001-11-29 | 2002-11-28 | Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP0105205 | 2001-11-29 | ||
HU0105205A HUP0105205A2 (en) | 2001-11-29 | 2001-11-29 | Pharmaceutical composition containing metformin and a hydroxylamine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003045387A1 true WO2003045387A1 (en) | 2003-06-05 |
Family
ID=89979939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2002/000132 WO2003045387A1 (en) | 2001-11-29 | 2002-11-28 | Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002347402A1 (en) |
HU (1) | HUP0105205A2 (en) |
WO (1) | WO2003045387A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103804309A (en) * | 2012-11-09 | 2014-05-21 | 广州喜鹊医药有限公司 | Chloroxime compound, its preparation method and application in pharmacy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5147879A (en) * | 1988-10-20 | 1992-09-15 | Biorex Kutato-Fejleszto Kft | O-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same |
WO1997016439A1 (en) * | 1995-11-02 | 1997-05-09 | Biorex Kutató és Fejlesztó Rt. | Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
-
2001
- 2001-11-29 HU HU0105205A patent/HUP0105205A2/en unknown
-
2002
- 2002-11-28 AU AU2002347402A patent/AU2002347402A1/en not_active Abandoned
- 2002-11-28 WO PCT/HU2002/000132 patent/WO2003045387A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5147879A (en) * | 1988-10-20 | 1992-09-15 | Biorex Kutato-Fejleszto Kft | O-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same |
WO1997016439A1 (en) * | 1995-11-02 | 1997-05-09 | Biorex Kutató és Fejlesztó Rt. | Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
Non-Patent Citations (1)
Title |
---|
KÜRTHY ET AL: "Effect of BRX-220 against Peripheral neuropathy and Insulin resistance in Diabteic Rat Models.", ANN. N:Y ACAD.SCI, vol. 967, - 2002, USA, pages 482 - 489, XP009010044 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103804309A (en) * | 2012-11-09 | 2014-05-21 | 广州喜鹊医药有限公司 | Chloroxime compound, its preparation method and application in pharmacy |
CN103804309B (en) * | 2012-11-09 | 2019-08-02 | 广州喜鹊医药有限公司 | A kind of chlorine oxime compound and preparation method thereof and the application in pharmacy |
Also Published As
Publication number | Publication date |
---|---|
AU2002347402A1 (en) | 2003-06-10 |
HUP0105205A2 (en) | 2003-08-28 |
HU0105205D0 (en) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2276604C2 (en) | Anti-diabetic preparation and method for treatment of diabetes mellitus | |
US5922769A (en) | Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II | |
TW565449B (en) | Pharmaceutical compositions for use in treating diabetes mellitus and conditions associated with diabetes mellitus | |
US6174925B1 (en) | Use of sibutramine analogues to prevent the development of diabetes | |
CA1228300A (en) | Galenic preparation forms for oral antidiabetic agents and processes for producing them | |
RU2275915C2 (en) | Method for diabetes treatment | |
DE69515038T2 (en) | USE OF RALOXIFEN AND ITS ANALOGS FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING VIRAL DISEASES | |
EA013084B1 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
EA015382B1 (en) | Use of roflumilast for the treatment of diabetes mellitus type 2 | |
JP2003519621A5 (en) | ||
IE57793B1 (en) | Orally administerable antidiabetic compositions | |
JPWO2006011397A1 (en) | Drugs for the prevention or treatment of diabetes | |
KR20200078353A (en) | Pharmaceutical composition comprising empagliflozin and sitagliptin | |
WO2021086292A1 (en) | Bilayer tablet formulations comprising dapagliflozin and metformin | |
AU596296B2 (en) | Treatment of diabetes | |
TW586926B (en) | A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal | |
WO2003045387A1 (en) | Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative | |
BG64817B1 (en) | Combination of thiazolidinedion and sulphonylurea, composition and usage thereof | |
EP1335731A2 (en) | Antidiabetic compositions containing a biguanide and a sulfonamide | |
KR20070104913A (en) | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes | |
CA2237571C (en) | A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii | |
US20060025478A1 (en) | Medicine for prevention or treatment of diabetes | |
WO2009035368A1 (en) | Antidiabetic pharmaceutical composition | |
JPH05170653A (en) | Treating agent for diabetes mellitus | |
WO2013002313A1 (en) | Weight control drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |